Krystal Biotech Inc（KRYS）資訊與事件KRYSKrystal Biotech Inc

Stock Futures Rise as Investors Improve Risk Appetite

Stock futures are higher as investors begin a new month with improving risk appetite after easing tensions in the Middle East sent oil prices sharply lower. Technology shares are helping lead the gains as investors look ahead to another busy week of corporate earnings and economic data.Geopolitical developments are driving sentiment after President Donald Trump announced a pause in military strikes against Iran and renewed diplomatic efforts aimed at reopening the Strait of Hormuz. Brent crude has fallen roughly 5% and U.S. crude has dropped below $80 per barrel. Treasury yields have also moved lower as investors scale back expectations for additional inflationary pressure from energy markets.Earnings season remains a catalyst, with investors awaiting results from Palantir after Monday's close, followed later this week by reports from AMD, McDonald's, Pfizer, Eli Lilly, Disney and Uber. The market is also preparing for SpaceX's first earnings report since its public listing. Recent results from Microsoft and Amazon have helped restore confidence in the AI trade, though investors remain sensitive to signs of rising capital expenditures and slowing returns on AI investments.Looking ahead, investors will monitor this week's economic calendar for fresh insight into the health of the U.S. economy. Friday's July employment report is expected to provide an important update on labor market conditions and could influence expectations for future Federal Reserve policy.In pre-market trading, S&P 500 futures rose 0.60%, Nasdaq futures rose 0.19% and Dow futures rose 1.20%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Atkoreup 28% after entering into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8BFergusonup 8% ahead of its entry into the S&P 500Supernusup 15% after the company and Indivior entered into a definitive agreement to combine in a tax-free all-stock merger of equals transactionIndiviorup 4% after Supernus and the company entered into a definitive agreement to combine in a tax-free all-stock merger of equals transactionBristol Myersup 3% after Financial TimesAstraZenecais in discussions to combine with the company in a deal valued at nearly $400BDOWN AFTER EARNINGS -Sportradardown 17%Krystal Biotechdown 5%Marriottdown 2%LOWER -AstraZenecadown 7% after Financial Timesthe company is in discussions to combine with Bristol Myers Squibb in a deal valued at nearly $400BCircle Internet (CRCL) down 6% after Morgan Stanley downgraded the stock to Underweight with a price target of $38, down from $106

Krystal Biotech Q2 Revenue $119.22M, Below Consensus

Reports Q2 revenue $119.22M, consensus $121.04M. "Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. "VYJUVEK is not only changing the standard of care for DEB patients around the world, it is also giving us the ability to advance high-conviction rare disease programs across the eye, lung, and skin with focus and discipline. We believe the next 12 to 18 months have the potential to mark an important transition for Krystal from a commercial success story to a multi-product genetic medicines company."

Berkshire Hathaway Acquires Taylor Morrison Home

Berkshire Hathaway (BRK.A/BRK.B) is acquiring Taylor Morrison Home (TMHC) in a deal expected to close on or about that date, pending final closing conditions.